Investigational drug · Phase 2
TX000045
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction, Hypertension, Pulmonary.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "TX000045"
First trial start
2024
Sep 4, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TX000045", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pulmonary Hypertension
- Heart Failure With Preserved Ejection Fraction
- Hypertension, Pulmonary
- Lung Diseases, Interstitial
Approved drugs for the same conditions: High blood pressure (hypertension) · Heart failure · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "TX000045" as an intervention, largest first.
- A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)Pivotal-lookingActive, not recruiting
Tectonic TherapeuticIndustry
NCT06616974 · 191 participants (planned) · Start Sep 4, 2024 · Primary completion Nov 24, 2026
Drug: TX000045- Dose A; TX000045- Dose B and 1 more · For: Pulmonary Hypertension; Heart Failure With Preserved Ejection Fraction
Sites: Phoenix, Arizona; Scottsdale, Arizona; San Francisco, California · 72 sites in all
- Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung DiseaseRecruiting
Tectonic Operating Company, Inc.Industry
NCT07473700 · 25 participants (planned) · Start Oct 30, 2026 · Primary completion Nov 21, 2027
Drug: TX000045 · For: Hypertension, Pulmonary; Lung Diseases, Interstitial
Sites: Phoenix, Arizona; San Francisco, California; Boise, Idaho · 16 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Development of a long-acting relaxin for the treatment of pulmonary hypertension.
Diener J, Soni H, Booe J, et al. · Br J Pharmacol 2026
Also in development for Pulmonary Hypertension
- INS1009Treprostinil PalmitilPhase 37 trials
Insmed Incorporated · Interstitial Lung Disease, Pulmonary Hypertension, Pulmonary Arterial Hypertension
- TNX-103Phase 33 trials
Tenax Therapeutics, Inc. · Pulmonary Hypertension Associated With HFpEF, Pulmonary Hypertension
- MosliciguatPhase 32 trials
Pulmovant, Inc. · Pulmonary Hypertension, Interstitial Lung Disease, Vascular Diseases
- RalinepagAPD811Phase 32 trials
United Therapeutics · PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension
- HS235Phase 22 trials
35Pharma Inc., a GSK company · Pulmonary Arterial Hypertension, Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.